Brachytherapy最新文献_第10页

PO87 PO87

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.188

Danilo Maziero, Catheryn Yashar, Jyoti Mayadev, Dominique Rash, Daniel Scanderbeg

{"title":"PO87","authors":"Danilo Maziero, Catheryn Yashar, Jyoti Mayadev, Dominique Rash, Daniel Scanderbeg","doi":"10.1016/j.brachy.2023.06.188","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.188","url":null,"abstract":"Purpose To propose a generalization of the known relationship between total reference air Kerma (TRAK) and isodose surface volumes for intracavitary, hybrid and interstitial applicators used for treating cervical cancer with high dose rate (HDR) brachytherapy (BT). Materials and Methods A single institution cohort of 123 retrospective clinical HDR BT plans from 34 patients treated for cervical cancer were evaluated. The cohort consisted of 71 intracavitary (tandem and ring - T&R - and tandem and ovoid - T&O), 32 hybrid (T&R or T&O with the addition of stainless steel and/or flexi needles) and 20 interstitial plans. Patients received 45Gy external beam radiotherapy (EBRT), followed by one of three fractionation schemes delivered with BT: 600cGy x 4 fractions (4 patients for a total of 16 fractions), 700cGy x 4 fractions (21 patients for a total of 80 fractions) and 800cGy x 3 fractions (9 patients for a total of 27 fractions). The average dose per fraction was 708.9±58.5cGy considering all 123 plans. For each plan the isodose surface volumes (TPSvol) were evaluated considering the accumulated EBRT and BT dose. Because three different fractionation schemes were used, the radiobiological equivalent doses in 2Gy fractions (EQD2) were estimated considering the EBRT and BT contributions. We have considered α/β ratio = 10Gy for tumor repair and repair half time T1/2 = 1.5 hour. In this work we have considered three reference dose levels (dref): 60Gy, 75Gy and 85Gy. Figure 1A-C illustrates the isodose surface volumes for the different fractionation schemes. The TRAK of each plan was also recorded. The relationship between TRAK/dref and TPSvol for the different applicators was evaluated by applying a second degree polynomial linear regression considering the two variables for each case. Results The linear regressions showed correlation coefficients R2 of 0.998, 0.997, 0.995 and 0.997 for the data obtained from treatments using intracavitary (Fig. 1D), hybrid (Fig. 1E), interstitials (Fig. 1F) and all applicators together (Fig. 1G), respectively. The linear regressions were not found to be affected by the different fractionation schemes. The quadratic, linear coefficients and the curve intercepts ranged from 0.621 to 0.739, 11.29 to 12.64 and -16.9 to -12.32, respectively. The fitted equation for the hybrid implants (Fig. 1E) showed the largest differences for the quadratic coefficient and curve intercept when compared to the equation fitted for intracavitary and interstitial applicators. The equation resulting from all applicators (Fig. 1G) showed the smallest differences for quadratic and linear coefficients when compared to the equation resulting intracavitary applicators. Conclusions We have shown that TRAK might be useful to predict volumes of isodose surfaces independently of the applicator and fractionation scheme used for treating cervical cancer with BT. The potential to use the correlation between TRAK and volumes of isodose surfaces to predict p","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO48 PO48

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.149

Rustica Cerillo, Amber Malloy, Mary Ann Monson, Lisa Thigpen, Kimberly DeBaun

引用次数: 0

PO46 PO46

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.147

Hayden Anthony Ansinelli, Arjit Baghwala, Chengfeng (Brandon) Li, Ramiro Pino, E. Brian Butler, Bin S. Teh, Andrew M. Farach

引用次数: 0

PO116 PO116

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.217

Mustafa M. Basree, Charles Wallace, Jessica Schuster, Jessica Miller, Michael Lawless, Juliet L. Aylward, Yaohui Xu, Kristin Bradley, Randall J. Kimple, Adam Burr

{"title":"PO116","authors":"Mustafa M. Basree, Charles Wallace, Jessica Schuster, Jessica Miller, Michael Lawless, Juliet L. Aylward, Yaohui Xu, Kristin Bradley, Randall J. Kimple, Adam Burr","doi":"10.1016/j.brachy.2023.06.217","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.217","url":null,"abstract":"Purpose Non-melanoma skin cancer is the most common cancer worldwide and its treatment in the elderly can pose significant challenges. We established a skin brachytherapy program primarily to treat older patients using the hypofractionated courses and superficial treatment depth afforded by this technique. Here we describe the first patients treated at our institution, including our initial oncologic results and toxicities. Materials and Methods This is a single-institution retrospective review of non-melanoma skin cancer patients treated at our institution from March 2020 to October 2022 with high dose rate brachytherapy with iridium-192. Either the 2 or 3 cm Valencia applicator was used to treat 25 of 27 lesions with a prescription depth of 3 mm. The Valencia was fixed in place using a clamp and patients were immobilized using a custom head sponge. The other two lesions were treated using a custom array of catheters in Aquaplast and a Freiburg flap. Baseline characteristics and treatment-related variables were summarized using descriptive statistics. Acute and late radiation toxicities were graded using RTOG Common Toxicity Criteria. Local control was evaluated using the Kaplan Meier method. Results Twenty-one patients were identified (n=11 F; n=10 M), with twenty-seven lesions. Median age 81 years (range, 55 to 104), with 85.2% basal- and 14.8% squamous-cell carcinoma. Median follow up was 10.1 months (1.0 to 31.8). Treated lesions were located on the face (n=14), head (n=6), lower extremity (n=5), and neck (n=2), with median lesion size of 8 millimeters (2.5 to 30). Patients were treated with median 40 Gy (40 to 48.5) in 8 fractions (5 to 16) prescribed to depth of 3 mm (3 to 5). RTOG grade 1 skin toxicity (mild erythema) was present in 17 lesions and grade 2 toxicity (brisk erythema) was present in 10 lesions. The most common late toxicity was hypopigmentation in 3 patients. One patient developed a late grade 3 ulcer in a poorly perfused lower limb. Local control was 95.7% on a per lesion basis at one year with a marginal failure in 1/27 lesions. Conclusions Our initial experience with non-melanoma skin brachytherapy has shown good local control with an acceptable safety profile in a predominantly elderly population. Treatment of non-melanoma skin cancers on the lower extremity in elderly patients remains an ongoing challenge due to the risk of late toxicity. Further studies are needed to compare the acute and late toxicity of surface brachytherapy to widely available external beam techniques such as electron beam radiation therapy. Currently, the excellent local control and short treatment courses provide a great treatment option for superficial, early stage non-melanoma skin cancers. Non-melanoma skin cancer is the most common cancer worldwide and its treatment in the elderly can pose significant challenges. We established a skin brachytherapy program primarily to treat older patients using the hypofractionated courses and superficial trea","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO103 PO103

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.204

Thomas Harris, Ivan M. Buzurovic, Evangelia Kaza, Desmond A. O'Farrell, Christian V. Guthier, Robert A. Cormack, Davide Brivio, Michael Lavelle, Phillip M. Devlin

{"title":"PO103","authors":"Thomas Harris, Ivan M. Buzurovic, Evangelia Kaza, Desmond A. O'Farrell, Christian V. Guthier, Robert A. Cormack, Davide Brivio, Michael Lavelle, Phillip M. Devlin","doi":"10.1016/j.brachy.2023.06.204","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.204","url":null,"abstract":"Purpose Dupuytren's contracture (DC) is an inflammatory disorder of the palm resulting in fascia thickening into nodules and cords. Although typically not painful, the cords can cause increased fixed flexion of one or more fingers (usually the 4th or 5th digits) to remain bent towards the palm. Prospective clinical trials have shown radiation's ability to stabilize or even improve symptoms in the majority of cases. Brachytherapy can be used to target the affected region while providing a rapid dose falloff to spare healthy tissue, and can also easily modulate treatment depth within the field. In some MRI sequences the cords yield a characteristic signal. This study examines if MR imaging in combination with surface applicator brachytherapy (SABT) may allow accurate targeting of the fibrosed region. Materials and Methods Five patients with DC, one with bilateral disease, underwent MR-guided surface applicator brachytherapy in our clinic. For each of the six hands, a CT simulation was performed followed immediately by MR scans. At simulation, the hand was palpated to locate the nodules and cords to be treated; up to a 2 cm margin was then applied and marked with a non-ferrous CT wire. A flap applicator was laid on top of the treatment region and secured with Coban wrap. A CT scan was acquired with the patient's hand stretched out over the head in swimmer's position, if tolerable. After CT and before unwrapping the applicator, the patient underwent MRI with a T1-weighted DIXON VIBE sequence, while in the same positioning. At treatment planning the catheters were reconstructed on the CT scan, which was then fused to the T1 DIXON VIBE in-phase scan for target evaluation. Treatment extent marked by CT wire was compared to MRI, and treatment depth was determined by the MRI findings. Patients received daily 3 Gy x 10 fxs, with a 6-8 week break following fraction 5, a common dose regime used in published literature. Results All six courses of radiation were well tolerated with no acute grade I toxicities. MRI target regions were all contained within the 2 cm margin marked at simulation. For CT-only treatment planning, our clinic prescribes to a uniform depth of 3 mm; however, the MRI showed localized increased depth of fibrosis up to a maximum of 8.5 mm, which was accounted for during treatment planning. The in-phase DIXON images were selected for treatment planning to avoid the phase cancellation artifact present at fat-water interfaces on the opposed-phase DIXON images, which nevertheless demonstrated higher flap applicator visibility. The possibility of MR-only SABT by combining different MR sequences and contrasts is being separately investigated. One patient was unable to accommodate the swimmer's position during simulation, and had his hand placed on his abdomen. That patient's MR was partially affected by motion artifacts but was still useful in target delineation. Conclusions MR-guided SABT for DC is feasible and well tolerated. MR information was","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO105 PO105

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.206

Irina Vasilievna Horot

{"title":"PO105","authors":"Irina Vasilievna Horot","doi":"10.1016/j.brachy.2023.06.206","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.206","url":null,"abstract":"There are few approaches in treatment of non-melanoma skin cancer: operation, external irradiation, brachytherapy, use of appropriate medications. In brachytherapy it is possible to use rigid needles, flexible applicators and application methods. As a rule the choice depends on many factors - size of the tumor, location, histology, previous treatments etc. Purpose The aim of the work was to evaluate the effectiveness of applicator method in brachytherapy of non melanoma skin cancer. In this report we evaluate the results of the application method in treatment of non melanoma skin cancer. Patients and Methods 86 patients have been treated since 2017 till 2020 years. Basalioma was diagnosed in 59 pts, squamous cell carcinoma - in 27 pts. 47 pts had tumor in head and neck region, 21 - in different sites of the body and 18 - in limbs. 9 pts had recurrence after operation. The location of the applicators was chosen individually, they were attached to an individual mask that repeats the curves of the body and provides a rigid fixation of the applicators during treatment. Total dose amounted to 36 Gy (6 Gy * 6 fraction, 1 fraction per day) . The dose planning was performed at Oncentra 4.0. Treatment was fulfilled at Microselectron (30 channels) HDR. Planning was done on the basis of CT images. Dose normalisation depended on many factors and ranged from 3 mm till 10 mm if there was a necessity. As a rule, reaction to irradiation began at different times after the start of treatment but the peak of reactions usually happens in approximately 10 days after treatment completion and were strongly dealt with the tumor location. Results The healing lasted for three months on average. As a result in 83 patients (97%) the treatment effect was good: full tumor regression with good cosmetic effect. In 3 patients prolongacion morbi was observed and tumor was reirradiated. During the first year patients were under control every 3 months and later - every 6 months. Conclusion With the correct choice of application method, the results of the treatment of non-melanoma cancer can be considered as good. There are few approaches in treatment of non-melanoma skin cancer: operation, external irradiation, brachytherapy, use of appropriate medications. In brachytherapy it is possible to use rigid needles, flexible applicators and application methods. As a rule the choice depends on many factors - size of the tumor, location, histology, previous treatments etc. The aim of the work was to evaluate the effectiveness of applicator method in brachytherapy of non melanoma skin cancer. In this report we evaluate the results of the application method in treatment of non melanoma skin cancer. 86 patients have been treated since 2017 till 2020 years. Basalioma was diagnosed in 59 pts, squamous cell carcinoma - in 27 pts. 47 pts had tumor in head and neck region, 21 - in different sites of the body and 18 - in limbs. 9 pts had recurrence after operation. The location of the applicators w","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO55 PO55

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.156

Valentine Ho, Sarat Chander, Scott Williams, Sylvia Van Dyk, Elizabeth Pu

{"title":"PO55","authors":"Valentine Ho, Sarat Chander, Scott Williams, Sylvia Van Dyk, Elizabeth Pu","doi":"10.1016/j.brachy.2023.06.156","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.156","url":null,"abstract":"Purpose Dose escalation with brachytherapy in combination with external beam radiotherapy (EBRT) improves long-term biochemical control in intermediate- and high-risk localised prostate cancer, and high dose rate brachytherapy (HDR) as monotherapy has been shown to be safe and effective in treating localised prostate cancer. We compare long-term efficacy and toxicity data for patients with unfavourable-intermediate and high-risk disease treated with HDR brachytherapy as boost (HDR-B) and HDR brachytherapy as monotherapy (HDR-M) between 2007 and 2018 at a single institution. Materials and Methods Retrospective record review was performed for sequential patients treated with HDR for localised prostate cancer from 20th March 2007 to 31st July 2018 after Human Research Ethics Committee approval. Recurrence and toxicity data was derived from medical records or direct patient contact where appropriate. Primary outcome measures included biochemical progression-free survival (bPFS), as defined by Phoenix criteria and toxicity, graded according to CTCAE v4.0. Multivariate regression using Cox proportional hazards model was performed to determine hazard ratio for bPFS between HDR-M and HDR-B groups. Results 268 patients with unfavourable-intermediate or high risk disease were identified, with 233 and 35 patients receiving HDR-B and HDR-M respectively. The median follow-up was 7.6 years for HDR-B and 5.1 years for HDR-M. Of 7 patients who received HDR-M with high risk disease, 5 had prior pelvic irradiation. In the HDR-B group, the brachytherapy dose delivered was 20Gy in 2 fractions in 94% of patients, and EBRT dose received was 46Gy in 23 fractions in 89%. The HDR-M dose delivered was 27Gy in 2 fractions (54.3%), 33Gy in 3 fractions (28.6%) and 34.5Gy in 3 fractions (14.3%). ADT was used in 71% of HDR-B patients, 37% of HDR-M patients, and 66% overall, with 43% receiving 12 months or more. The bPFS was 85.6% ((95% confidence interval [CI] 79.6%-90.0%) at 5 years and 71.8% (95% CI 62.1%-79.4%) at 10 years for HDR-B, and 77.5% (95% CI 58.1%-88.7%) at 5 years and 53.3% (95% CI 26.2%-74.4%) at 10 years for HDR-M, with a multivariate hazard ratio of 2.10 (p=0.08). Significant predictors of biochemical failure were primary tumour stage, Gleason grade group, and ADT use, with hazard ratios of 1.3 (p=0.01), 1.4 (p=0.03) and 0.6 (p=0.02). At 5 and 10 years, overall survival was 94% and 87% for HDR-B and 96% and 69% for HDR-M. The crude urethral stricture rate was 15.9% (n=37, 95% CI 11.7%-21.2%) for HDR-B, 11.4% (n=4, 95% CI 4.2%-27.5%) for HDR-M and 15.3% (95% CI 11.4%-20.1%) overall, with 39 requiring intervention at a median time of 2.2 years. Of the four patients in HDR-M group experiencing stricture, two had prior pelvic irradiation as risk factors. The overall rate of stricture was 25% (95% CI 17.7%-33.5%) with a median follow-up of 11.5 years for patients treated before 2010, and 8% (95% CI 4.5%-13.5%) with a median follow-up of 5.9 years for those treated ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO58 PO58

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.159

Lauren M. Andring, Brandon Li, Arjit Baghwala, Ramiro Pino, Bin S. Teh, E Brian Butler, Andrew M. Farach

{"title":"PO58","authors":"Lauren M. Andring, Brandon Li, Arjit Baghwala, Ramiro Pino, Bin S. Teh, E Brian Butler, Andrew M. Farach","doi":"10.1016/j.brachy.2023.06.159","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.159","url":null,"abstract":"Background/Purpose After radical prostatectomy 30% of men will develop biochemical recurrence. Typical salvage is with external beam radiation (EBRT) or ADT. Treatment options for a second recurrence, after salvage EBRT are limited. Prostate fossa brachytherapy (BT) offers a dosimetrically favorable treatment option that is convenient for patients and cost effective. However, there is limited data to guide management. This report describes the technique of using HDR BT salvage for prostate fossa recurrence. Methods Eligible patients had pathologically confirmed local recurrence or elevated PSA and visible lesion on PSMA PET, with no evidence of distant metastatic disease, and were suitable candidates for BT implant. Trans-rectal ultrasound (TRUS) guided volume study was performed, extending 1cm cranial and caudal to the most distant aspects of disease. The target was delineated and a 3mm circumferential planning target volume margin was added with no expansion superiorly, inferiorly, or posteriorly. A pre-plan was created to assess normal tissue tolerances and plan for presumptive needle distribution to achieve an acceptable D90. Based on disease location and size, an appropriate perineal template was selected. TRUS guidance was used for implant insertion intra-operatively with real-time plan optimization as needed. Post-operatively, the perineal template was secured, and patients underwent CT simulation to confirm appropriate needle placement. Based on the CT scan, needle depth was adjusted, the target was contoured, and the plan was optimized. Results At a single institution 7 patients completed prostate fossa HDR BT salvage between June 2020 to January 2023. BT was utilized as definitive salvage for re-irradiation (re-RT) of a second local recurrence (n=5), or as a boost to escalate dose for initial recurrence (n=2). For definitive re-RT, prescription dose was most commonly 30Gy/5fx delivered twice daily (BID) (Figure 1a), other dose regimens used include 32Gy/4fx BID, 27Gy/2fx, and 23Gy/1fx. Boost dose was 30Gy/5fx BID if close to normal tissues or 15Gy/1fx (Figure 1b) after 46-50.4Gy EBRT. Dose constraints included rectal D1cc <75% and urethral D1cc<110% with cumulative D2cc assessed to account for prior radiation. The median pre-treatment PSA was 3.75ng/ml and median post-treatment PSA was 0.52ng/ml. Three (42%) patients had acute grade 1-2 genitourinary (GU) toxicity and one patient had a late grade 3 event involving stress incontinence requiring an artificial sphincter. Conclusion Brachytherapy salvage for prostate fossa recurrence is safe and feasible. This report describes the dose, target, and technique for successful utilization in the setting of initial salvage dose escalation and re-RT for a second recurrence. Future prospective studies are required to further elucidate associated disease outcomes. After radical prostatectomy 30% of men will develop biochemical recurrence. Typical salvage is with external beam radiation (EBRT) or AD","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"105 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PO39 PO39

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.140

Asmita Kulshrestha, Krishna Ratanchandani, Sonal Patel Shah

引用次数: 0

PO05 PO05

Brachytherapy Pub Date : 2023-09-01 DOI: 10.1016/j.brachy.2023.06.106

Allison Hazy, Hong Ye, Megan Mansour, Andrew Zureick, Stefany Acosta-Torres, Zaid Al-Wahab, Jill Gadzinski, Kevin McCool, Barry Rosen, Sirisha Nandalur, Maha Saada Jawad

引用次数: 0